Engelthaler, David M.
https://orcid.org/0000-0001-5945-059X
Mayo Clinic
Translational Genomics Research Institute
Citations 1
A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.
Borazanci, Erkut , Jameson, Gayle , Downes, Michael , Truitt, Morgan , Patel, Hitendra , Lowy, Andrew M. , Roe, Denise J. , Ansaldo, Karen, Barrett, Michael T. , Korn, Ronald L. , Caldwell, Lana, Slethaug, Gavin, Hultsch, Rolf, Han, Haiyong , Engelthaler, David M. , Lenkiewics, Elizabeth, Hoff, Daniel D. Von , Borazanci, Erkut , Chung, Vincent , Evans, Ronald M. , Patel, Hitendra, Pearson, Talima
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4154-TPS4154
